KALVISTA PHARMACEUTICALS LTD

SP4 0JQ (South West)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£2,267,005

May 15 - May 18

Clinical development to PoC of a novel oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME)

Innovate UK award to KALVISTA PHARMACEUTICALS LTD and Sally Hampton

£149,364

Feb 14 - Jul 15

The development of a companion diagnostic to improve patient management and pharmacoeconomics in diabetic retinopathy

Innovate UK award to KALVISTA PHARMACEUTICALS LTD and Sally Hampton

£2,400,000

Dec 12 - Nov 15

Pre-clinical development of novel oral plasma kallikrein inhibitors for the treatment of diabetic macular edema

Innovate UK award to KALVISTA PHARMACEUTICALS LTD and Sally Hampton

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}